Scalper1 News
Gilead Sciences (GILD) stock was rebounding in afternoon trading on the stock market today, as an analyst lifted his Q3 forecast for sales of blockbuster hepatitis C drug Sovaldi. FBR analyst Andrew Berens raised his estimate to $2.24 billion from $1.94 billion after examining August prescription data from health industry research firm Symphony Health Solutions. After a record-breaking launch following U.S. approval last December, Sovaldi’s sales Scalper1 News
Scalper1 News